Last updated: February 21, 2026
What is the Drug?
NDC 00548-5400 corresponds to Eptacog alfa (recombinant), marketed as NovoSeven RT. It functions as a recombinant activated factor VII used to treat bleeding episodes in hemophilia patients with inhibitors, surgical bleeding, or trauma-related hemorrhages.
Market Size and Dynamics
Patient Population
- Hemophilia A and B with inhibitors: Estimated at 4,000–6,000 patients in the U.S. and European markets.
- Surgical and trauma settings: Utilization depends on the volume of surgeries and trauma incidents but is comparatively niche.
Competitive Landscape
- Key competitors:
- Baxalta/Shire’s (Takeda) Adynovent (similar indications)
- Eptacog alpha (recombinant) variants from multiple manufacturers
- Other bypassing agents such as FEIBA (Factor VIII inhibitor bypass activity) and FEIBA.
Market Trends
- An increase in hemophilia inhibitor cases drives demand.
- Advances in manufacturing reduce costs, improving access.
- Expansion into emerging markets, with regulatory approvals increasing.
Historical Pricing and Market Projections
Current Price Benchmarks
- U.S. average wholesale price (AWP): Approximately $16,000 to $20,000 per vial.
- Dosing: Typically 1–2 mg per dose; treatment courses range from 1 to 8 doses depending on bleeding severity.
Price Trends (Past 5 Years)
| Year |
Average Price per Vial |
Notes |
| 2018 |
~$16,500 |
Stable, with minor fluctuations. |
| 2019 |
~$16,700 |
Slight increase linked to manufacturing costs. |
| 2020 |
~$16,800 |
Pandemic-driven supply chain considerations. |
| 2021 |
~$17,000 |
Price stability maintained. |
| 2022 |
~$17,200 |
Slight inflation, driven by demand and rarity. |
Projected Price Range (Next 3 Years)
| Year |
Estimated Price per Vial |
Assumptions |
| 2023 |
$17,200 – $17,500 |
No major regulatory or manufacturing disruptions. |
| 2024 |
$17,300 – $17,700 |
Potential generic or biosimilar entry influences pricing. |
| 2025 |
$17,500 – $18,000 |
Slight inflation, increased utilization in emerging markets. |
Continuously, biosimilar competition could enter the space by 2024–2025, potentially reducing prices by 10–20%.
Regulatory and Market Factors Impacting Future Pricing
- Biosimilar approval: Must meet FDA standards; expected by 2024–2025.
- Patent expirations: No active patent expiry until late 2024 or early 2025, allowing for some price stabilization.
- Reimbursement policies: Price adjustments depend on payer negotiations.
- Treatment guidelines: Shifts toward personalized medicine might influence dosing and supply.
Key Drivers and Risks
- Increase in hemophilia inhibitor prevalence.
- Market entry of biosimilars.
- Changing reimbursement landscapes.
- Advancements in gene therapy could reduce demand.
Summary
- The drug's current wholesale price hovers around $17,000 per vial.
- Market growth primarily driven by hemophilia inhibitor cases and emerging markets.
- Price increases are modest barring regulatory or competitive disruptions.
- Biosimilar entry expected within 2 years could pressure prices downward.
Key Takeaways
- NDC 00548-5400’s market is stable but faces competition from biosimilars.
- Prices are likely to increase gradually, contingent on demand and regulatory dynamics.
- The emerging markets, innovation in hemophilia management, and biosimilar availability will influence long-term pricing.
FAQs
1. What are the primary uses for NovoSeven RT?
Treats bleeding in hemophilia patients with inhibitors, surgical bleeding, and trauma-related hemorrhages.
2. How does biosimilar competition influence pricing?
Entry of biosimilars can reduce prices by 10–20% within 1–3 years of approval.
3. Is the current price sustainable?
Yes, given the niche market, high clinical demand, and regulatory protections until new biosimilars enter.
4. What factors could significantly alter pricing in the future?
Regulatory approvals for biosimilars, new treatment guidelines favoring alternative therapies, and market expansion into unpenetrated regions.
5. How does the pricing compare globally?
European prices are roughly 10–15% lower than U.S. prices due to different reimbursement models and pricing regulations.
References
[1] Food and Drug Administration. (2023). NovoSeven (Eptacog alfa recombinant). Retrieved from https://www.fda.gov
[2] IQVIA. (2023). Biologic and specialty drug market reports.
[3] McKinsey & Company. (2022). Biosimilar market evolution and Price impacts.
[4] Harvard Business Review. (2021). Biologics pricing trends and market dynamics.
